Grail: Gautam Kollu
Grail has appointed Gautam Kollu as chief commercial officer. Kollu previously served as VP of global market development at Illumina. Before Illumina, Kollu served as VP of marketing, medical affairs, and business development at Natera. Prior to Natera, he served as VP of commercial at Exelixis and worked in several marketing and commercial roles at Genentech.
Seven Bridges: Michael Bigda
Seven Bridges has named Michael Bigda chief operating officer, filling a vacancy left when previous COO William Moss was elevated to CEO in March. Bigda previously served as senior manager for mergers and acquisitions at industrial tool and consumer hardware manufacturer Stanley Black & Decker. Before that, he was senior VP of operations at Delphi Technology, a maker of software for the medical professional liability market.
Mammoth Biosciences: Peter Nell, Ted Tisch
Mammoth Biosciences has appointed Peter Nell as chief business officer and head of therapeutics, and has named Ted Tisch chief operations officer.
Nell has previously served in various positions at Casebia Therapeutics and Bayer HealthCare. In his new role at Mammoth, he will scale the company's CRISPR offerings. Nell is a chemist by training, and is listed as co-inventor on more than 45 patents, and author or co-author of several scientific publications and book contributions in the biomedical field.
Tisch joins Mammoth after four years at Synthego, where he established the product development, manufacturing operations, and commercial program for two CRISPR-based product lines. He previously served as vice president and general manager for Bio-Rad Laboratories' protein function division.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.